Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis.
暂无分享,去创建一个
M. Gaub | L. Brugières | N. Entz-Werlé | P. Lutz | C. Stoetzel | F. Perrin-Schmitt | J. Gentet | P. Oudet | M. Tabone | C. Schmitt | H. Pacquement | C. Kalifa | T. Lavaux | A. Babin | Nadia Metzger | Christelle Lasthaus | Perrine Marec | F. Perrin‐Schmitt
[1] M. Gaub,et al. KIT gene in pediatric osteosarcomas: Could it be a new therapeutic target? , 2007, International journal of cancer.
[2] D. Vanel,et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. , 2007, European journal of cancer.
[3] J. Nährig,et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] N. Malats,et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Birchmeier,et al. Aberrant Wnt/beta-catenin signaling can induce chromosomal instability in colon cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[6] L. Naldini,et al. MET overexpression turns human primary osteoblasts into osteosarcomas. , 2006, Cancer research.
[7] R. Cheney,et al. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[8] C. Hartmann. A Wnt canon orchestrating osteoblastogenesis. , 2006, Trends in cell biology.
[9] Zhixiang Liao,et al. The Wnt-inducible Transcription Factor Twist1 Inhibits Chondrogenesis* , 2006, Journal of Biological Chemistry.
[10] M. Heymann,et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice , 2005, Cancer.
[11] A. Puisieux,et al. A twist for survival and cancer progression , 2005, British Journal of Cancer.
[12] M. Gaub,et al. Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas , 2005, International journal of cancer.
[13] C. Eberhart,et al. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. , 2005, Cancer research.
[14] Y. Yen,et al. Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. , 2005, World journal of gastroenterology.
[15] D. Silbergeld,et al. TWIST is expressed in human gliomas and promotes invasion. , 2005, Neoplasia.
[16] C. Colnot. Cellular and molecular interactions regulating skeletogenesis , 2005, Journal of cellular biochemistry.
[17] Xiaomeng Zhang,et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. , 2005, Cancer research.
[18] Carl W. Miller,et al. Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes. , 2005, Cancer genetics and cytogenetics.
[19] Wei Liu,et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. , 2005, Endocrinology.
[20] M. Ittmann,et al. The Fibroblast Growth Factor Receptor-4 Arg388 Allele Is Associated with Prostate Cancer Initiation and Progression , 2004, Clinical Cancer Research.
[21] A. Ullrich,et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma , 2004, International journal of cancer.
[22] D. Heymann,et al. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. , 2004, Trends in molecular medicine.
[23] S. Ramaswamy,et al. Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.
[24] H. Yoshikawa,et al. Bone morphogenetic proteins in bone tumors , 2004, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.
[25] H. Inoue,et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high‐grade soft tissue sarcoma , 2003, Cancer.
[26] P. Terrier,et al. Genetic alterations in primary osteosarcoma from 54 children and adolescents by targeted allelotyping , 2003, British Journal of Cancer.
[27] J. Helms,et al. Molecular ontogeny of the skeleton. , 2003, Birth defects research. Part C, Embryo today : reviews.
[28] Z. Hořejší,et al. The twist gene is a common target of retroviral integration and transcriptional deregulation in experimental nephroblastoma , 2003, Oncogene.
[29] H. Höfler,et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. , 2002, Cancer research.
[30] P. Ducy. Contrôle génétique de la squelettogenèse , 2001 .
[31] C. Hartmann,et al. Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2 , 2001, Mechanisms of Development.
[32] P. Ducy. CBFA1: A molecular switch in osteoblast biology , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.
[33] D. Jacqmin,et al. Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. , 2000, Cancer research.
[34] D. Rice,et al. Integration of FGF and TWIST in calvarial bone and suture development. , 2000, Development.
[35] D. Rice,et al. Molecular mechanisms in calvarial bone and suture development, and their relation to craniosynostosis. , 1999, European journal of orthodontics.
[36] D. Bishop,et al. K‐ras mutation and loss of heterozygosity of the adenomatous polyposis coli gene in patients with colorectal adenomas with in situ carcinoma , 1999, Cancer.
[37] E. Canalis,et al. Fibroblast growth factor-2 induces hepatocyte growth factor/scatter factor expression in osteoblasts. , 1999, Endocrinology.
[38] B. Crombrugghe,et al. Toward understanding SOX9 function in chondrocyte differentiation. , 1998 .
[39] R. Baron,et al. Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation , 2005 .
[40] R. Altman,et al. Hepatocyte growth factor and its actions in growth plate chondrocytes. , 1996, Bone.
[41] D. Ornitz,et al. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia , 1996, Nature Genetics.
[42] G. Dorn,et al. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. , 1995, Molecular biology of the cell.
[43] P. Lollini,et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. , 1995, Oncogene.
[44] G. Grasselli,et al. Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. , 2006, European journal of cancer.
[45] M. Koutsilieris,et al. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells. , 2006, Anticancer research.
[46] G. Gordon,et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. , 2006, Cancer research.
[47] K. Ogasawara,et al. Detection of gene amplification and deletion in high-grade gliomas using a genome DNA microarray (GenoSensor Array 300) , 2006, Brain Tumor Pathology.
[48] J. Wood. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. , 2000, Medicina.
[49] V. Lefebvre,et al. Toward understanding SOX9 function in chondrocyte differentiation. , 1998, Matrix biology : journal of the International Society for Matrix Biology.
[50] G. Karsenty,et al. Genetics of skeletogenesis. , 1998, Developmental genetics.
[51] P. Bénit,et al. Mutations of the TWIST gene in the Saethre-Chotzene syndrome , 1997, Nature Genetics.